Latest News & Publications
Media Center
Connect with us and get the latest news on how AsclepiX Therapeutics is working to develop life-transforming medicines to make hope a reality for patients in need
AsclepiX Therapeutics Announces $35 Million Series A Financing
Proceeds to fund development of AXT107 for treatment of retinal diseases through Phase 1/2a clinical trials Series A financing led by the Perceptive Xontogeny Venture Fund BALTIMORE, MD, June 24,…
Read More AsclepiX Therapeutics, Inc. Expands Leadership Team with Appointment of Industry Leader Theresa Heah, MD, MBA as Chief Medical Officer.
Monday, January 6, 2020 8:00 AM BALTIMORE, MD – AsclepiX Therapeutics, Inc., a biopharmaceutical company that uses computational biology to identify potent peptide regulators of vascular and cellular homeostasis for…
Read More AsclepiX Therapeutics Raises $5M in New Funding. Financing will advance clinical development of the Company’s lead product AXT107.
Financing will advance clinical development of the Company’s lead product AXT107 BALTIMORE – AsclepiX Therapeutics, Inc., a biopharmaceutical company focused on developing vital new therapies based on a novel peptide…
Read More AsclepiX Therapeutics Selected to Present at Ophthalmology Innovation Summit (OIS) at the American Society for Retinal Surgeons (ASRS) Annual Conference.
BALTIMORE, MD / ACCESSWIRE / July 16, 2019 / AsclepiX Therapeutics, Inc., a biopharmaceutical company focused on the use of artificial intelligence (AI) to discover, design, develop, and deliver novel…
Read More AsclepiX Therapeutics, Inc. Strengthens Board of Directors, Welcomes Steven M. Altschuler, MD
BALTIMORE, MD – AsclepiX Therapeutics, Inc, a biopharmaceutical company focused on developing vital new therapies based on a novel collagen IV-derived peptide called AXT107, announces that Steven Altschuler, MD has…
Read More AXT107 Restores Healthy, Non-Leaky Vasculature in the Eye by Inhibiting VEGFR2 and Activating Tie2, the Two Clinically Validated Pathways in Diseases of the Retina.
BALTIMORE, MD – AsclepiX Therapeutics, Inc., a biopharmaceutical company focused on developing vital new peptide therapies, including a novel collagen IV-derived peptide called AXT107, announces the publication of a study…
Read More Scientific Publications
AXT107 Publications
A collagen IV–derived peptide disrupts α5β1 integrin and potentiates Ang2/Tie2 signaling.
Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage.
Suppression of Ocular Vascular Inflammation through Peptide-Mediated Activation of Angiopoietin-Tie2 Signaling.
AXT201 Publications
Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide.
AXT301 & AXT501 Publications
AXT301 – Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth…
AXT301 – Collagen IV and CXC chemokine-derived antiangiogenic peptides suppress glioma xenograft growth
AXT501 – Inhibition of lymphangiogenesis and angiogenesis in breast tumor xenografts and lymph nodes by a peptide derived from transmembrane protien 45A
